
Sep 7, 2026
Episode 15: Rethinking RRP--Are We Entering A New Era? With Dr. Simon Best

Episode 15: Rethinking RRP--Are We Entering A New Era? With Dr. Simon Best
In this episode of the UEP Voicebox podcast, we dive deep into the evolving landscape of recurrent respiratory papillomatosis (RRP) with leading laryngologist Dr. Simon Best. Specializing in complex voice and airway disorders—with a particular focus on the comprehensive care of professional voice-users and performers—Dr. Best shares invaluable clinical insights into shifting paradigms of patient care.
Join host Dr. Shiying Hey as we explore emerging medical interventions, including HPV-specific immunotherapy (Papzimeos), bevacizumab, and vaccination protocols. Dr. Best outlines a modern, forward-thinking treatment algorithm designed with three core goals: reducing procedural frequency, safeguarding vocal function, and fundamentally improving patient quality of life.
What We Cover in This Episode:
-
The Clinical Burden of RRP: Understanding the physical and emotional toll on patients.
-
The Recurrence Cycle: Exploring the underlying drivers behind why RRP keeps coming back.
-
The RRPF Contemporary Treatment Approach: Integrating state-of-the-art strategies into daily practice (featuring extended insights on Bevacizumab).
-
A Paradigm Shift: Evaluating HPV-specific immunotherapy and how it changes the therapeutic landscape.
-
Mechanism of Action: A closer look at how HPV-specific immunotherapy works at the cellular level.
-
The Johns Hopkins Experience: Real-world clinical outcomes and observations utilizing Papzimeos.
-
Looking Ahead: The future horizon of RRP care and ongoing research.
Listen now to explore the future of airway and vocal rehabilitation. Don't forget to subscribe, share, and stay connected with our community as we continue exploring the intersection of science and the human voice.
Missed an episode? Catch up here on all the conversations recorded at The UEP Voicebox, the official podcast of The Union of European Phoniatricians.
No comments yet. Be the first to say something!